Another significant update is the definition of a new subtype of myelodysplastic neoplasm with biallelic TP53 inactivation, resulting in the reclassification of 53 patients—most of them previously defined as myelodysplastic syndrome with excess blasts (34 out of 53 patients). This evidence concerns the gene TP53 and myelodysplastic syndrome.